A Phase 2 trial is testing a weekly intranasal spray that primes early immune defenses to reduce respiratory virus illness.

This chart summarizes the case name, presiding judge, drug, and patents-at-issue in all federal district court cases that are ...

The recall is classified as Class III, the FDA’s lowest risk level, meaning it's "not likely to cause adverse health consequences." ...

Can’t hurt, just might save a life. That’s the idea behind the city of Hollywood’s partnership with the Robin Foundation, a nonprofit working with the city to install emergency overdose cabinets ...

The University of Maryland is studying a new approach to reducing respiratory infections. Clinical trials are about to start ...

Company highlights accelerating access and revenue growth for ARBLI™ and confirms REZENOPY™ launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million ...

The Option awards are subject to the award holder’s continuous service through each vesting date and to the terms and conditions of the Plan and its standard forms of grant agreements thereunder.

Nine recommendations for extending therapeutic indications reflect ongoing lifecycle management and utility expansion of ...

If you type a "W" into your search engine and it autofills with "Why does my..." or "What should I..." — this post is for you ...

Leaders say a new $100,000 visual data system will help the fire department track outcomes to overdose calls, including the success of administering naloxone, a medicine that reverses opioid overdoses ...